Updated recommendations for the management of metabolic dysfunction–associated steatotic liver disease (MASLD) by the Latin American working group
Top Cited Papers
Open Access
- 13 March 2025
- journal article
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 101903
Abstract
No abstract availableKeywords
Funding Information
- Agencia Nacional de Investigación y Desarrollo
- Fondo Nacional de Desarrollo Científico y Tecnológico (1241450)
- Novo Nordisk
This publication has 216 references indexed in Scilit:
- Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without CirrhosisJAMA, 2024
- Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic SteatohepatitisJAMA, 2021
- Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver DiseaseJAMA Internal Medicine, 2019
- The Physical Activity Guidelines for AmericansJAMA, 2018
- Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver DiseaseJAMA Internal Medicine, 2016
- Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With DiabetesJAMA, 2015
- Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetesHepatology, 2014
- Fatty liver index and mortality: The cremona study in the 15th year of follow-upHepatology, 2011
- The NAFLD fibrosis scoreHepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006